FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 191 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Strong Independent Association of TILs with OS for Patients with ERBB2-positive... February 26, 2025 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 The 10 Things That Helped Me Cope With My 2 Cancer... February 6, 2024 A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... January 12, 2026 Load more HOT NEWS Imaging Test Could Help Guide Breast Cancer Treatment Decisions Patients With DCIS Reduce Risk Of Recurrence And Death If They... New on NCI’s Websites for October 2019 Age and Frailty Should Be Considered Independently When Evaluating Potential Risk...
